These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36434811)

  • 1. Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy.
    Hansen-Barkun C; Martel M; Douketis J; Abraham NS; Liederman Z; Kaplovitch E; Schulman S; Spyropoulos AC; Majid A; Barkun AN
    Am J Gastroenterol; 2023 May; 118(5):812-819. PubMed ID: 36434811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant.
    Douketis JD; Spyropoulos AC; Duncan J; Carrier M; Le Gal G; Tafur AJ; Vanassche T; Verhamme P; Shivakumar S; Gross PL; Lee AYY; Yeo E; Solymoss S; Kassis J; Le Templier G; Kowalski S; Blostein M; Shah V; MacKay E; Wu C; Clark NP; Bates SM; Spencer FA; Arnaoutoglou E; Coppens M; Arnold DM; Caprini JA; Li N; Moffat KA; Syed S; Schulman S
    JAMA Intern Med; 2019 Nov; 179(11):1469-1478. PubMed ID: 31380891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale.
    Douketis JD; Spyropoulos AC; Anderson JM; Arnold DM; Bates SM; Blostein M; Carrier M; Caprini JA; Clark NP; Coppens M; Dentali F; Duncan J; Gross PL; Kassis J; Kowalski S; Lee AY; Le Gal G; Le Templier G; Li N; MacKay E; Shah V; Shivakumar S; Solymoss S; Spencer FA; Syed S; Tafur AJ; Vanassche T; Thiele T; Wu C; Yeo E; Schulman S
    Thromb Haemost; 2017 Dec; 117(12):2415-2424. PubMed ID: 29212129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
    Schaefer JK; Errickson J; Li Y; Kong X; Alexandris-Souphis T; Ali MA; Decamillo D; Haymart B; Kaatz S; Kline-Rogers E; Kozlowski JH; Krol GD; Shankar SR; Sood SL; Froehlich JB; Barnes GD
    JAMA Intern Med; 2021 Jun; 181(6):817-824. PubMed ID: 33871544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation.
    Kawabata M; Goya M; Maeda S; Yagishita A; Takahashi Y; Sasano T; Hirao K
    Int Heart J; 2020 Sep; 61(5):905-912. PubMed ID: 32921660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periendoscopic management of direct oral anticoagulants: a prospective cohort study.
    Radaelli F; Fuccio L; Paggi S; Hassan C; Repici A; Rondonotti E; Semeraro R; Di Leo M; Anderloni A; Amato A; Trovato C; Bravi I; Buda A; de Bellis M; D'Angelo V; Segato S; Tarantino O; Musso A; Fasoli R; Frazzoni L; Liverani E; Fabbri C; Di Giulio E; Esposito G; Pigò F; Iannone A; Dentali F;
    Gut; 2019 Jun; 68(6):969-976. PubMed ID: 30064986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Lakkireddy D; Reddy YM; Di Biase L; Vanga SR; Santangeli P; Swarup V; Pimentel R; Mansour MC; D'Avila A; Sanchez JE; Burkhardt JD; Chalhoub F; Mohanty P; Coffey J; Shaik N; Monir G; Reddy VY; Ruskin J; Natale A
    J Am Coll Cardiol; 2012 Mar; 59(13):1168-74. PubMed ID: 22305113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
    Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
    Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
    Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study.
    Tapaskar N; Ham SA; Micic D; Sengupta N
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):381-389.e9. PubMed ID: 33227428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
    J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
    Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
    Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery.
    Siscos SM; Neill BC; Singh AH; Hocker TLH
    J Am Acad Dermatol; 2021 Feb; 84(2):425-431. PubMed ID: 33045293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
    Adeboyeje G; Sylwestrzak G; Barron JJ; White J; Rosenberg A; Abarca J; Crawford G; Redberg R
    J Manag Care Spec Pharm; 2017 Sep; 23(9):968-978. PubMed ID: 28854073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.